Albanian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

The United Kingdom Multiple Sclerosis Register Covid-19 Substudy

Vetëm përdoruesit e regjistruar mund të përkthejnë artikuj
Identifikohuni Regjistrohu
Lidhja ruhet në kujtesën e fragmenteve
StatusiRekrutimi
Sponsorët
Swansea University

Fjalë kyçe

Abstrakt

The aim of the study is to understand the impact of COVID-19 on People with Multiple Sclerosis in the United Kingdom.

Përshkrim

Study objectives

1. To identify the incidence of upper respiratory tract symptoms: fever, cough and breathing difficulties, other symptoms suggestive of COVID-19 infection, respiratory tract infections suggestive of COVID-19, and COVID-19 confirmed by laboratory testing among the UK MS population

2. To establish if some DMDs increase the risk of COVID-19 infection

3. To determine the incidence and effectiveness of self-isolation in the MS population. To examine the impact self-isolation has on mood, fatigue, and other routinely collected patient reported outcome measures from the MS Register.

4. To determine the clinical outcome of respiratory tract infections, including confirmed and suspected cases of COVID-19, in terms of symptoms, time to recovery, hospital admission, requirement for ventilation, and death.

5. To determine the longer-term impact of COVID-19 on MS, using routinely collected MS outcomes in the MS register, including impact on disability, relapses and changes in DMDs as assessed at 3 monthly intervals.

6. To determine where people are obtaining their health information during the COVID-19 outbreak.

7. To establish changes in DMDs prior to and as a result of symptoms related and unrelated to COVID-19

Datat

Verifikuar së fundmi: 02/29/2020
Paraqitur së pari: 04/05/2020
Regjistrimi i vlerësuar u dorëzua: 04/19/2020
Postuar së pari: 04/20/2020
Përditësimi i fundit i paraqitur: 06/18/2020
Përditësimi i fundit i postuar: 06/21/2020
Data e fillimit të studimit aktual: 03/13/2020
Data e vlerësuar e përfundimit primar: 07/13/2021
Data e vlerësimit të përfundimit të studimit: 07/13/2022

Gjendja ose sëmundja

Multiple Sclerosis
COVID-19

Faza

-

Grupet e krahëve

KrahNdërhyrja / trajtimi
Confirmed Cases
Diagnosed by health professional / Covid-19 test Monitored through fortnightly questionnaires
Not Covid-19 cases
Through self report no suspicion of COVID-19, tested by fortnightly questionnaire. non Covid Cases can become COVID cases through self report.
Suspected Covid-19 Cases
Participants that are suspected of having Covid-19 but this has not been confirmed by health professional or Covid-19 test has not been performed. Fortnighly questionnaire

Kriteret e pranimit

Moshat e pranueshme për studim 18 Years Për të 18 Years
Gjinitë e pranueshme për studimAll
Metoda e marrjes së mostrësNon-Probability Sample
Pranon Vullnetarë të Shëndetshëmpo
Kriteret

Inclusion Criteria:

- >18 and confirmed diagnosis of MS, enrolled on UK MS Register

Exclusion Criteria:

- None of the above

Rezultati

Masat Kryesore të Rezultateve

1. Incidence of COVID-19 Infections within an MS Cohort in the UK [Through study completion, an average of 1 year]

Targeted questionnaire dependent on COVID Status

2. Hospitalisations in MS Patients with COVID-19 [1 Year (regular outputs)]

Monitor admission rates in linked population

3. Mortality [1 Year from study commencement]

Death data from routinely reported government level data (HES/PEDW)

Masat dytësore të rezultateve

1. Patient Reported Expanded Disability Status Score [1 year (at least 6 monthly)]

Patient Reported Outcome for MS disability

2. Hospital Anxiety and Depression Scale [1 year (at least 6 monthly)]

Patient Reported Outcome for anxiety and depression

3. Multiple Sclerosis Impact Scale 29 V2 [1 year (at least 6 monthly)]

Patient Reported Outcome for Multiple sclerosis impact on physical and psychological status

4. Multiple Sclerosis Walking Scale 12 V2 [1 year (at least 6 monthly)]

Patient Reported Outcome for walking status

5. Fatigue Severity Scale [1 year (at least 6 monthly)]

Patient Reported Outcome for impact of fatigue

6. EuroQol 5D (3l) [1 year (at least 6 monthly)]

Patient Reported Outcome for general quality of life

Bashkohuni në faqen
tonë në facebook

Baza e të dhënave më e plotë e bimëve medicinale e mbështetur nga shkenca

  • Punon në 55 gjuhë
  • Kurime bimore të mbështetura nga shkenca
  • Njohja e bimëve nga imazhi
  • Harta GPS interaktive - etiketoni bimët në vendndodhje (së shpejti)
  • Lexoni botime shkencore në lidhje me kërkimin tuaj
  • Kërkoni bimë medicinale nga efektet e tyre
  • Organizoni interesat tuaja dhe qëndroni në azhurnim me kërkimet e lajmeve, provat klinike dhe patentat

Shkruani një simptomë ose një sëmundje dhe lexoni në lidhje me barërat që mund të ndihmojnë, shtypni një barishte dhe shikoni sëmundjet dhe simptomat që përdoren kundër.
* I gjithë informacioni bazohet në kërkimin shkencor të botuar

Google Play badgeApp Store badge